Cancer Chemotherapy and Pharmacology

, Volume 53, Issue 6, pp 482–488 | Cite as

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

  • P. C. Adamson
  • S. M. Blaney
  • B. C. Widemann
  • B. Kitchen
  • R. F. Murphy
  • A. L. Hannah
  • G. F. Cropp
  • M. Patel
  • A. F. Gillespie
  • P. G. Whitcomb
  • F.M. Balis
Original Article

Abstract

Purpose

To determine the maximum tolerated dose and the toxicity profile of the PDGF receptor pathway inhibitor SU101 in pediatric patients with refractory solid tumors, and to define the plasma pharmacokinetics of SU101 and its active metabolite SU0020 in children.

Experimental design

Patients between 3 and 21 years of age with CNS malignancy, neuroblastoma, or sarcoma refractory to standard therapy were eligible. The starting dose of SU101 was 230 mg/m2 per day administered as a 96-h continuous infusion every 21 days. Blood for pharmacokinetic analysis was obtained during the first cycle.

Results

Entered into the trial were 27 patients, and 24 were fully evaluable for toxicity. Dose-limiting central nervous system toxicity was observed in two patients at the 440 mg/m2 per day dose level. Non-dose-limiting toxicities included nausea, vomiting, headache, fatigue, abdominal discomfort, diarrhea, pruritus, anorexia, constipation, and paresthesias. There were no complete or partial responses. One patient with rapidly progressive desmoplastic small round-cell tumor experienced symptomatic improvement and prolonged stable disease. Steady-state concentrations of SU101 were rapidly achieved and proportional to dose. The concentration of SU0020 was 100- to 1000-fold greater than that of SU101. The median clearance of SU0020 was 0.19 l/day per m2 and its terminal elimination half-life was 14 days.

Conclusions

SU101 administered on this schedule was generally well tolerated. The maximum tolerated dose of SU101 is 390 mg/m2 per day for 4 days repeated every 3 weeks. The neurotoxicity observed at the 440 mg/m2 per day dose level suggests that patients receiving repetitive cycles must be monitored closely, as SU0020 may accumulate over time.

Keywords

Signal transduction Pharmacokinetics Pediatric SU101 Leflunomide 

References

  1. 1.
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ (1997) Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5- methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167–1177PubMedGoogle Scholar
  2. 2.
    Westermark B, Heldin CH (1993) Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol 32:101–105PubMedGoogle Scholar
  3. 3.
    Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219PubMedGoogle Scholar
  4. 4.
    Heldin CH (1992) Structural and functional studies on platelet-derived growth factor. EMBO J 11:4251–4259PubMedGoogle Scholar
  5. 5.
    Westermark B, Heldin CH, Nister M (1995) Platelet-derived growth factor in human glioma. Glia 15:257–263PubMedGoogle Scholar
  6. 6.
    Harsh GR, Keating MT, Escobedo JA, Williams LT (1990) Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines. J Neurooncol 8:1–12PubMedGoogle Scholar
  7. 7.
    Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A, Nister M (1996) Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56:164–171PubMedGoogle Scholar
  8. 8.
    Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, Schlessinger J, Westermark B (1988) Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48:3910–3918PubMedGoogle Scholar
  9. 9.
    Antoniades HN, Galanopoulos T, Neville-Golden J, O’Hara CJ (1992) Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci U S A 89:3942–3946PubMedGoogle Scholar
  10. 10.
    Chung CK, Antoniades HN (1992) Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res 52:3453–3459PubMedGoogle Scholar
  11. 11.
    Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B (1993) Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69:682–689PubMedGoogle Scholar
  12. 12.
    Ponten F, Ren Z, Nister M, Westermark B, Ponten J (1994) Epithelial-stromal interactions in basal cell cancer: the PDGF system. J Invest Dermatol 102:304–309PubMedGoogle Scholar
  13. 13.
    Forsberg K, Bergh J, Westermark B (1993) Expression of functional PDGF beta receptors in a human large-cell lung-carcinoma cell line. Int J Cancer 53:556–560PubMedGoogle Scholar
  14. 14.
    Holmgren L, Flam F, Larsson E, Ohlsson R (1993) Successive activation of the platelet-derived growth factor beta receptor and platelet-derived growth factor B genes correlates with the genesis of human choriocarcinoma. Cancer Res 53:2927–2931PubMedGoogle Scholar
  15. 15.
    Funa K, Nordgren H, Nilsson S (1991) In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. Scand J Urol Nephrol 25:95–100PubMedGoogle Scholar
  16. 16.
    Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131–140PubMedGoogle Scholar
  17. 17.
    Plate KH, Breier G, Farrell CL, Risau W (1992) Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67:529–534PubMedGoogle Scholar
  18. 18.
    Wainer IW, Granvil CP, Wang T, Batist G (1994) Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Res 54:4393–4397PubMedGoogle Scholar
  19. 19.
    Seymour L, Dajee D, Bezwoda WR (1993) Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26:247–252PubMedGoogle Scholar
  20. 20.
    Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550–4554PubMedGoogle Scholar
  21. 21.
    Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors [see comments]. J Clin Oncol 17:1095–1104PubMedGoogle Scholar
  22. 22.
    VanUmmersen L, Ness E, Goldstein DJ, Disbrow G, Metlay G, Shawver L, Hannah AL, Marshall JL (1997) A phase I trial of SU101 in patients with solid tumors (meeting abstract). Proc ASCO p A740Google Scholar
  23. 23.
    Malkin MG, Mason WP, Lieberman FS, Hannah AL (1997) Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma (meeting abstract). Proc ASCO p A1371Google Scholar
  24. 24.
    Shapiro W, Ashby L, Obbens E, Isaacs J, Cropp G, DePaoli A, Hannah A (1999) A phase I/II study of SU101 in combination with carmustine (BCNU) in the treatment of patients newly diagnosed with malignant glioma (meeting abstract). Proc ASCO p A548Google Scholar
  25. 25.
    Malkin MG, Rosen L, Lopez AM, Mulay M, Cloughesy T, Hannah AL (1998) Phase 2 study of SU101, a PDGF-R signal transduction inhibitor, in recurrent malignant glioma (meeting abstract). Proc ASCO p A1504Google Scholar
  26. 26.
    Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ (2001) A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 7:800–805PubMedGoogle Scholar
  27. 27.
    Ko YJ, Chachoua A, Small E, Reese D, Kabbinavar F, Taneja S, DePaoli A, Hannah A, Balk S, Bubley G (1999) Phase II study of SU101 in patients with PSA-positive prostate cancer (meeting abstract). Proc ASCO p A1220Google Scholar
  28. 28.
    Rosen L, Lopez AM, Mulay M, Chap L, Prager D, Pegram M, Rosen P, Hannah AL (1997) A phase I/II study of SU101 in patients with ovarian, prostate, and non-small cell lung cancers (meeting abstract). Proc ASCO p A739Google Scholar
  29. 29.
    Chap L, Chachoua A, Lopez A, DePaoli A, Hannah A (1999) A phase II study of SU101 in patients with advanced ovarian cancer (meeting abstract). Proc ASCO p A1437Google Scholar
  30. 30.
    Kabbinavar F, Hannah A, Rosen P, Sawyers C, Prager D, Baker C, DePaoli A, Cropp G (1999) Phase I trial of SU101 in combination with mitoxantrone in the treatment of patients with hormone refractory prostate cancer. Clin Cancer Res 5:3800SGoogle Scholar
  31. 31.
    Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, Roessner A (1995) Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 141:97–103PubMedGoogle Scholar
  32. 32.
    Froberg K, Brown RE, Gaylord H, Manivel C (1999) Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci 29:78–85PubMedGoogle Scholar
  33. 33.
    Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber DA (1997) The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet 17:309–313PubMedGoogle Scholar
  34. 34.
    Froberg K, Brown RE, Gaylord H, Manivel C (1998) Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci 28:386–393PubMedGoogle Scholar
  35. 35.
    Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900–1908PubMedGoogle Scholar
  36. 36.
    Wheldon LM, Nahorski SR, Willars GB (2001) Inositol 1,4,5-trisphosphate-independent calcium signalling by platelet-derived growth factor in the human SH-SY5Y neuroblastoma cell. Cell Calcium 30:95–106CrossRefPubMedGoogle Scholar
  37. 37.
    Pahlman S, Johansson I, Westermark B, Nister M (1992) Platelet-derived growth factor potentiates phorbol ester-induced neuronal differentiation of human neuroblastoma cells. Cell Growth Differ 3:783–790PubMedGoogle Scholar
  38. 38.
    Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H, Nakamura H, Chihara K (1993) Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest 92:1153–1160PubMedGoogle Scholar
  39. 39.
    Palman C, Bowen-Pope DF, Brooks JJ (1992) Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 66:108–115PubMedGoogle Scholar
  40. 40.
    National Cancer Institute (1993) Guidelines for reporting adverse drug reactions. Cancer Therapy Evaluation Program Division of Cancer Treatment, Investigator’s Handbook. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD. Appendix XIIGoogle Scholar
  41. 41.
    Rozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41:421–430PubMedGoogle Scholar
  42. 42.
    Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA, Williamson RA, Ruuth E (1998) Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 336:299–303PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • P. C. Adamson
    • 1
    • 4
  • S. M. Blaney
    • 2
  • B. C. Widemann
    • 1
  • B. Kitchen
    • 1
  • R. F. Murphy
    • 1
  • A. L. Hannah
    • 3
  • G. F. Cropp
    • 3
  • M. Patel
    • 1
  • A. F. Gillespie
    • 1
  • P. G. Whitcomb
    • 1
  • F.M. Balis
    • 1
  1. 1.Pediatric Oncology BranchNational Cancer InstituteBethesdaUSA
  2. 2.Texas Children’s Cancer Center/Baylor College of MedicineHoustonUSA
  3. 3.Sugen Inc.San FranciscoUSA
  4. 4.Clinical Pharmacology and TherapeuticsThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations